Schrödinger (NASDAQ: SDGR) is a long way from its $99.50 peak reached in July. The stock fell because the company posted a strong second-quarter report that beat consensus estimates. It then readied an equity offering to take advantage of the share appreciation.
Full Answer
Why are investors ditching Schrodinger stock?
Mar 04, 2021 · Schrodinger (NASDAQ:SDGR) is currently down 26.84% to a price of $74.5. The stock's current volume for the day is 4.39 million, which is approximately 508.31% of its previous 30-day average volume ...
How much is a share of Schrödinger worth?
May 09, 2022 · Negative. Very Negative. Source. Headline. $38.67 Million in Sales Expected for Schrödinger, Inc. (NASDAQ:SDGR) This Quarter. marketbeat.com - May 6 at 5:08 AM. Schrödinger (NASDAQ:SDGR) Hits New 12-Month Low at $22.50. americanbankingnews.com - May 8 at 3:48 AM. Schrödinger (NASDAQ:SDGR) Shares Gap Up After Strong Earnings.
Who is the CEO of Schrödinger?
Apr 15, 2022 · Their forecasts range from $49.00 to $91.00. On average, they anticipate Schrödinger's share price to reach $68.50 in the next twelve months. This suggests a possible upside of 173.7% from the stock's current price. View analysts' price targets for Schrödinger or view top-rated stocks among Wall Street analysts.
When did Schrödinger go public?
Nov 11, 2021 · So Schrödinger is still gazing into the crystal ball and seeing business growth. It proffered guidance for full-year 2021 of $124 million to $134 million in total revenue, which represents solid ...
Is Schrodinger a good stock to buy?
Will Schrodinger stock go up?
The 8 analysts offering 12-month price forecasts for Schrodinger Inc have a median target of 67.50, with a high estimate of 88.00 and a low estimate of 34.00. The median estimate represents a +189.58% increase from the last price of 23.31.
Why did Sdgr go down?
Who bought Schrodinger stock?
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 7.57% | +55,184 |
| ARK Investment Management LLC | 4.75% | +654,146 |
| BlackRock Fund Advisors | 4.46% | +108,689 |
| Credit Suisse Securities (USA) LL... | 4.02% | +124,702 |
How does Schrodinger Inc make money?
How do I invest in Schrodinger?
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. ...
- Research the stock. ...
- Purchase now or later. ...
- Check in on your investment.
What does Schrödinger company do?
What does Schrödinger Inc do?
Is Bill Gates still invested in Schrodinger?
Bill Gates's position in Schrodinger is currently worth $205 Million. That's 0.85% of their equity portfolio (13th largest holding). The investor owns 9.26% of the outstanding Schrodinger stock. The first Schrodinger trade was made in Q1 2020.
Did Bill Gates sell Schrodinger?
Did Bill Gates invest in Schrodinger?
Is Schrödinger a buy right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Schrödinger in the last twelve months. There are currently 2 hold...
How has Schrödinger's stock price been impacted by Coronavirus?
Schrödinger's stock was trading at $35.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization....
When is Schrödinger's next earnings date?
Schrödinger is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Schrödinger .
How were Schrödinger's earnings last quarter?
Schrödinger, Inc. (NASDAQ:SDGR) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.49) EPS for the quarte...
What guidance has Schrödinger issued on next quarter's earnings?
Schrödinger updated its FY 2022 earnings guidance on Thursday, March, 10th. The company provided earnings per share (EPS) guidance of for the perio...
What price target have analysts set for SDGR?
7 Wall Street analysts have issued 12-month price objectives for Schrödinger's stock. Their forecasts range from $49.00 to $104.00. On average, the...
Who are Schrödinger's key executives?
Schrödinger's management team includes the following people: Dr. Ramy Farid , CEO, Pres & Director (Age 56, Pay $1.01M) Dr. Richard A. Friesner...
What is Ramy Farid's approval rating as Schrödinger's CEO?
8 employees have rated Schrödinger CEO Ramy Farid on Glassdoor.com . Ramy Farid has an approval rating of 95% among Schrödinger's employees. This...
Who are some of Schrödinger's key competitors?
Some companies that are related to Schrödinger include Bausch Health Companies (BHC) , Grifols (GRFS) , Sarepta Therapeutics (SRPT) , Arena Pha...
About Schrödinger
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery.
Schrödinger (NASDAQ:SDGR) Frequently Asked Questions
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Schrödinger in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock.
What happened
Healthcare tech stock Schrödinger ( SDGR -5.26% ) was looking a bit sickly Thursday. After the company reported third-quarter earnings that missed on both the top and bottom lines, investors sold out of the shares, leaving the stock with a nearly 12% decline on the day.
So what
For the quarter, Schrödinger booked revenue of $29.9 million. While that was up by 16% on a year-over-year basis, it didn't meet the average analyst estimate of just under $31.6 million.
Now what
So Schrödinger is still gazing into the crystal ball and seeing business growth. It proffered guidance for full-year 2021 of $124 million to $134 million in total revenue, which represents solid if unspectacular improvement over 2020's $108 million.
Analysts Estimate Schrodinger, Inc. (SDGR) to Report a Decline in Earnings: What to Look Out for
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is it a Wise Move to Buy Schrödinger (SDGR) Shares?
Baron Funds, an asset management firm, published its “Baron Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of 6.56% was delivered by the fund’s institutional shares for the fourth quarter of 2021 and 15.84% for the year. This exceeded the Fund’s primary benchmark, the Russell […]
Meet a Portland scientist quietly developing drugs to beat cancer
Leah Frye started her professional life as a chemistry professor at Rensselaer Polytechnic Institute but soon realized she could have a more direct impact outside of academia. Two career stops later, she landed at Schrödinger, a biotech company that is headquartered in New York but that has offices around the world, including one in Portland.
The Petri Dish: Thermo Fisher taps Olaris, bluebird drugs delayed
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
Hudson Value Partners, LLC Buys Jackson Financial Inc, MKS Instruments Inc, Financial Select ..
Investment company Hudson Value Partners, LLC (Current Portfolio) buys Jackson Financial Inc, MKS Instruments Inc, Financial Select Sector SPDR, DT Midstream Inc, Sonos Inc, sells CorePoint Lodging Inc, Sherwin-Williams Co, Schrodinger Inc, iShares MSCI Switzerland ETF, Dow Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hudson Value Partners, LLC..
Schrödinger, Inc. (NASDAQ:SDGR) Is Expected To Breakeven In The Near Future
Schrödinger, Inc. ( NASDAQ:SDGR ) is possibly approaching a major achievement in its business, so we would like to...
Cullinan Associates Inc Buys Crown Castle International Corp, Electronic Arts Inc, Garmin, ..
Louisville, KY, based Investment company Cullinan Associates Inc (Current Portfolio) buys Crown Castle International Corp, Electronic Arts Inc, Garmin, Exxon Mobil Corp, Cognizant Technology Solutions Corp, sells International Business Machines Corp, Accenture PLC, Truist Financial Corp, Chevron Corp, Lowe's Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cullinan Associates Inc..
Is Schrodinger a profitable company?
The company also grew its customer count to 1,463 last year, up from 1,266 a year ago. Capital-wise, Schrodinger is profitable. In 2020, its operating cash flow amounted to $16.76 million, a significant improvement over the negative $26.05 million in operating cash flow it brought in 2019.
What are the problems with Schrodinger?
One of the main problems with Schrodinger is that its software is only applicable during the drug discovery phase. The principal investigator tests the drugs on study participants and assumes the research and development expenses after it advances to the clinical stage.
Is Schrodinger a top performing company?
For the past five years, Schrodinger ( NASDAQ:SDGR) has been one of the top-performing life sciences technology companies, with its stock almost quadrupling during the period.
Is Schrodinger a bargaining power?
Since the failure rate is very high for the combinatorial drug discovery method, Schrodinger isn't left with much bargaining power on its pricing, despite having many clients . To mitigate this, the company has a much smaller segment that involves collaboration with pharmaceuticals on drug discovery programs.
How many candidates did Schrodinger have in 2019?
It had 25 such candidates in 2019, with two oral tablets for the treatment of leukemia advancing to regulatory approval. Schrodinger receives compensation in the form of research fees, discovery and clinical milestone payments, and potential future commercial milestones and single-digit percentage royalties.
What happens if one or more brings a product or drug past the regulatory hurdle?
If one or more brings a product or drug past the regulatory hurdle, Schrodinger's stock could jump. Finally, the method of combinatorial chemistry isn't just applicable to drugs and medicines, but also toward the discovery of new materials.
Who tests the drugs on study participants and assumes the research and development expenses after it advances to the clinical stage?
The principal investigator tests the drugs on study participants and assumes the research and development expenses after it advances to the clinical stage. Since the failure rate is very high for the combinatorial drug discovery method, Schrodinger isn't left with much bargaining power on its pricing, despite having many clients.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
What's Happening With SDGR Stock Today?
Schrodinger Inc (SDGR) stock has fallen -0.83% while the S&P 500 has risen 0% as of 10:05 AM on Wednesday, Aug 18. SDGR is down -$0.46 from the previous closing price of $55.25 on volume of 66,764 shares. Over the past year the S&P 500 has risen 31.52% while SDGR is down -18.97%. SDGR lost -$0.60 per share in the over the last 12 months.
More About Schrodinger Inc
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries.